Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm still in here. Just some song lyrics of John Lennon.
Looks like you have about 4-6 months to get back in, probably at a lower price.
No longer riding on the merry go round, I just had to let it go
Yup Yosemite....I think
I don't even know which one. Is it Looney Tunes Yosemite Sam? If I had to guess.
LOL, probably only a few of us old enough to remember that cartoon. Classic.
Do you know on top of the 23.7% healthcare businessman's ownership of NextPlat, Dawson James Securities, Progressive Care's Investment Bank that specializes in Life Science and Health Care also owns a total 19.1% of NextPlat between Robert Kyser, Ark Financial and Sixth Borough Capital (all these three parties are tied to Dawson James Securities). So combined with Phillip Frost's shares, we have total 42.8% ownership of NextPlat that's directly invested in Healthcare industry. GO RXMD.
https://markets.businessinsider.com/stocks/nxpl-stock
Jason Kolbert is a senior healthcare analyst and the Director of Research at Dawson James. Jason will leverage his unique and diversified experiences to work across the Dawson James platform to augment the research product focusing on small and middle capitalized emerging growth companies utilizing Dawson James’ “Diversified Investor Offering™”, building their shareholder base with a combination of retail and institutional accounts.
https://dawsonjames.com/analyst-team/
He recently appeared on BNN Bloomberg talking about his expectations of the healthcare market. He specifically mentioned big pharma companies are "shopping microcap and emergent growth sectors of specialty pharma (4'15" - 4':32")
https://www.bnnbloomberg.ca/video/traditional-pharma-is-a-great-defensive-play-amid-this-market-uncertainty-health-care-analyst~2667707
Thanks, SF that's good to know...
Do you know with the purchase of 3,428,571 shares of NextPlat's common stock, Phillip Frost, an extremely successful entrepreneur and billionaire in healthcare industry, now owns 23.7% of NextPlat, the second largest shareholder of the company. Charles Fernandez owns 27.6%. Between the two, they own 51.3% of the company. Healthcare will be NextPlat's core business after they spin off the current Sat. business. RXMD will be the core of the core of NextPlat.
https://markets.businessinsider.com/stocks/nxpl-stock
https://ir.nextplat.com/sec-filings/all-sec-filings/content/0001493152-23-011111/0001493152-23-011111.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171691579
Guess point is that everyone was so excited when we had that little run a few weeks ago… where are we now? Right back what we started and heading lower
Ohh yeah? Find someone willing to pay 50% higher than current at that same volume
I wouldn't worry about a 180 share trade. Look at the spread...MMs are playing. Let's see where it closes.
I can make this up 50% on the same volume. So?
Down 34%…. What a day, what a joke
Follow the big money.
He bought the shares before Charles invested in RXMD. That means he knows his money will be used for such investment.
He's not stoopid, NXPL is the top shelf whiskey while RXMD is just the water chaser.
I wish he owned those shares in RXMD.
Roland Palmer, the top Alibaba executive, does not hold any position at NextPlat, but he owns more than 760,000 shares of NXPL, that’s more than $1.7M at the current stock price. Actually he spent at least $3.5M when he purchased these shares. Do not tell me he was given these shares by the company. Of cuz he was not. All the other board members paid for their own shares. Ellenoff is an exception, but he is an employee. Palmer is not.
Do you know Roland Palmer, Alibaba's Managing Director for UK, Netherlands and Nordic countries, is a 5.2% stockholder of NextPlat?
Let this Sink in. Why a top Alibaba executive director is holding more than 5% of NXPL and is willing to be reported on the proxy for the world to see?
https://content.equisolve.net/sec/0001493152-23-011075/formdef14a.htm
"The Chinese Alibaba Group has promoted Roland Palmer to general manager for the United Kingdom, the Netherlands and the Nordic countries.
Palmer succeeds David Lloyd, who recently left the Chinese e-commerce company. The Dutchman started at Alibaba in 2016 as Benelux director, with the main task of showing businesses the way to Tmall. He was later appointed head of Europe for payments subsidiary Alipay, The Retail Bulletin reports."
https://www.retaildetail.eu/news/general/roland-palmer-becomes-alibabas-managing-director-uk-netherlands-and-nordic-countries/
"“You can boost your business through export, but you do have to learn how to do it.
5/31/2023
In a recent interview , we spoke to Roland Palmer, General Manager of UK, Benelux & Nordics at the Alibaba Group. Roland elaborated on the findings of Alibaba’s recent survey into the UK export market and told us about what support UK SMEs need to boost their export sales."
https://www.businessleader.co.uk/boost-business-through-export-but-have-to-learn-how-to-do-it/
https://www.linkedin.com/in/roland-palmer-74528b/
I really don't think so either, as far as the overall market cap. However, it did hurt the stock in terms of volume. Many penny players just don't like buying stock in the dollars, which reduces liquidity for long termers, if you need to get out. Just my opinion.
Honest question, would the price be doing any better had there not been a RS? I don’t think so, with the lack of news so far this year.
Shhhhh don't tell eveyone!
You can say whatever you want. I will keep loading to the bank.
Loading, loading, loading. lol. I just keep loading.
Yep and now we have a 6 month Chinese dangling carrot! This company's motto is "soon".
Another shitty week here. Anyways longs got srewed by the RS (under false justification) and newcomers flip between $2 and $5pps with no end in sight
What have I become, my sweetest friend? Everyone I know goes away, in the end.
Take it easy
I don't have even have a TV.
Everyone enjoy the weekend. Stay cool.
There you go
Bard AI:
Progressive Care Inc. is a healthcare management company headquartered in Miami, Florida. It was founded in 2004 and is traded on the OTCQB Markets under the ticker symbol RXMD. The company provides a variety of healthcare services, including medication therapy management (MTM), pharmacy services, and health practice risk management. Progressive Care Inc. has over 200 employees and operates in 10 states.
In 2022, Progressive Care Inc. reported total revenue of $40.6 million, an increase of 5% from the previous year. Prescription revenue increased by 7% to $36.3 million, and 340B contract revenue increased by 100% to $3.8 million. The company's debt interest rate was reduced by 5% in 2022.
Progressive Care Inc. is a leading provider of MTM services in the United States. The company's MTM program is designed to improve patient outcomes and reduce healthcare costs. Progressive Care Inc.'s MTM program has been recognized by several organizations, including the National Council for Prescription Drug Programs (NCPDP) and the American Pharmacists Association (APhA).
Progressive Care Inc. is a well-established healthcare management company with a solid financial foundation. The company is a leader in the MTM market and is well-positioned for continued growth in the future.
Here are some of the company's key services:
Medication therapy management (MTM): Progressive Care Inc.'s MTM program is designed to improve patient outcomes and reduce healthcare costs. The program includes medication reviews, medication adherence counseling, and patient education.
Pharmacy services: Progressive Care Inc. provides a variety of pharmacy services, including prescription filling, medication delivery, and specialty pharmacy services.
Health practice risk management: Progressive Care Inc. provides health practice risk management services to help healthcare providers protect themselves from financial losses. These services include risk assessment, insurance placement, and claims management.
If you are looking for a healthcare management company with a solid track record of success, Progressive Care Inc. is a good option to consider. The company has a wide range of services to offer, and its MTM program is one of the best in the industry.
Well your average Joe would have to sell for a loss and relinquish long term capital gains. Better off buying NXPL, though it seems the two companies will become one ultimately.
The current Alibaba agreement will expire on July 20, about 50 days out. Charles said they will put out a lot of news related to joint ventures over the next 60-90 days. Link this with what this article said: "Onboarding businesses in all of the Americas could quickly snowball as more and more companies join the NextPlat initiative of new e-commerce profitability and success stories about the program emerge." It's easy to see they will renew the agreement after July 20 with Alibaba because more and more companies will form joint venture with NextPlat. Big healthcare companies will definitely be part of these deals. Just sit tight and/or load more. Big days are coming.
https://web3mediawire.com/nextplat-corp-nasdaq-nxpl-celebrates-great-day-in-miami-with-more-on-the-way/
I will not do this. The partnership/joint venture is for RXMD too. This will pop even harder than NXPL when the right news hit.
If you can you probably own both.
Is there any positive argument for selling RXMD to buy NXPL? Any thoughts?
Thank goodness, I need money
RXMD has been Trading Lowwwwwwwwwwwwww...
Just Beginning
Stock I would also add that increased revenue was also a moving factor, and if people can’t see that this will continue to increase month by month they must have their eyes closed.
I am with you. I think this will be well worth the wait. Most are not adding until it's all spelled out for them. It will be hard to catch when that happens.
Yes SF, the next couple of months will be very interesting for sure...partnerships, joint ventures, revenue increase will bring in investors and money.
Doubled on still weak volume. There hasn’t been any meaningful move in quite some time
It doubled up on the day when the Alibaba agreement news was announced. What will happen if they start announcing many many more major real partnership and joint venture news that will actually bring in much higher revenue? This is mind boggling if nobody can see what is about to come.
Followers
|
745
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
194638
|
Created
|
01/09/11
|
Type
|
Free
|
Moderators gedi8 Truth022809 stockforce TrackDude MrMike241 |
Progressive Care Gains SEC Reporting Status
See on website
Miami, FL – April 12, 2022 – Globe Newswire via NewMediaWire – Progressive Care, Inc. (OTCQB: RXMD) (the “Company”), a personalized healthcare services and technology provider, today announced that, effective April 11, 2022, its Registration Statement on Form 10 filed with the U.S. Securities and Exchange (the “SEC”) to register its shares of common stock under Section 12(g) of the Securities Exchange Act of 1934 (the “Exchange Act”) became automatically effective.
The effective Form 10 obligates the Company to file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, in addition to complying with all other obligations under the Exchange Act. In addition, management and certain shareholders are subject to the beneficial ownership reporting requirements of Section 13 and 16 of the Exchange Act.
Alan Jay Weisberg, Chairman and Chief Executive Officer of the Company said, “For me, it was always important to have the Company become fully reporting with the SEC. I know how critical it is for individual and institutional investors to have the Company file its financial reports with the SEC as it provides a higher level of confidence in the information reported by the Company and a superior level of transparency. I believe that the Company’s compliance with the Exchange Act will ultimately help drive shareholder value and enable us to access higher quality institutional capital. We remain committed to strong corporate governance and steadfast in pursuit of our journey to Nasdaq.”
To view the Form 10 filling, please click:
https://www.sec.gov/Archives/edgar/data/0001402945/000149315222009357/form10-12ga.htm
Key Financial Highlights for Year Ended December 31, 2021
• Revenue at $38.9 million
- COVID-19 testing revenue of approximately $4.3 million
- ClearMetrX TPA and pharmacy dispensing revenue related to 340B earned $2.8 million on total billings of $19 million
• Gross margin increased to 26% in 2021, from 23% in 2020
• EBITDA increased to $167,000 in 2021 from $7,000 in 2020
• Cash balance of $1.4 million as of December 31, 2021
Business Highlights for the Year Ended December 31, 2021
• Re-implemented upgraded pharmacy software system
• Expanded COVID-19 business into corporate-focused services and institutional clients
• Strengthened reputation in the 340B sector by adding eight new contracts
• Filed initial S-1 registration statement
• Submitted application for uplisting to Nasdaq
Q4 2021 Reflected a Positive Bounce Back in Business
• Increase of 10% in prescription revenue to $8.9 million in the fourth quarter of 2021, from $8.1 million in the third quarter of 2021
• Increase of 8% in prescriptions filled to 114,000 in the fourth quarter of 2021, from 106,000 in the third quarter of 2021
PRODUCTS AND SERVICES
Advances in HIV/AIDS treatment has greatly increased the ability of those suffering from the disease to manage their symptoms and live longer, healthier lives. Effective management of the disease begins with taking the right medications with the right dose at the right times. For those in the HIV/AIDS community, adhering to the very strict dietary and medicinal requirements can be extremely difficult. Normal activities are often interrupted and sometimes prevented by the struggle to be in compliance.
PharmCo wants to ease this burden on those impacted by this life altering disease. We aim to make compliance with prescription regiments as easy as possible. By understanding the sensitive nature of HIV/AIDS and the needs of those afflicted, PharmCo provides the following services to patients with these special needs:
1. Confidential packaging
2. Packaging tailored to suit a patient's individual life style
3. Free delivery from a variety of sources including PharmCo's proprietary delivery fleet
4. A staff that is well trained in acute illnesses, who understands the patient's needs and
concerns
5. 24 hour emergency support
6. Timely availability of specialty medications due to our extensive inventory
7. Access to newly developed medications
PharmCo is a fully accredited DME supplier. In November 2010, as part of Medicare's competitive bidding, PharmCo was awarded a three year contract to supply hospital beds, oxygen supplies, power wheelchairs, scooters, walkers, and other related equipment and accessories in South Florida. PharmCo carries an extensive inventory of equipment and accessories with most special requests being honored with same day or next day delivery. The company offers both sales and rentals with size, color, style, and brand options available on the majority of products. Most importantly, the staff is knowledgeable, helpful and dedicated to providing superior customer service.
PharmCo offers home service and maintenance, defective product replacements, and free home installation and instruction.
PharmCo's institutional clients have come to depend on the company's proven accuracy, dispensing methods, and immediate response time. With PharmCo compliance and efficiency assistance, long term care institutions are able to provide the highest level of continued care to their patients. PharmCo provides purchasing, repackaging and dispensing of both prescription and non-prescription pharmaceutical products. PharmCo utilizes a unit-of-dose packaging system as opposed to traditional vials used for its retail customers. This method of distribution improves control and patient compliance with recommended drug therapy by increasing the timeliness and accuracy of medication dispensing. PharmCo also provides computerized maintenance of patient prescription histories, third party billing and consultant pharmacist services. Its consulting services consist primarily of evaluation of monthly patient drug therapy and monitoring the institution’s drug distribution system.
Long term care institutions can count on PharmCo for the following services:
1. On time, same day deliveries available twice a day with 24 hour emergency support
2. Language assistance in English, Spanish, French, Creole, Portuguese, Russian, and Hebrew
3. Unit-dose packaging options tailored the facility's needs
4. Prescription data accuracy
5. Extensive medication and DME inventory
6. Access to OTC medications, nutritional products and personal hygiene items
7. Provision and review of medication carts
8. Monthly pharmacy consultations- drug interactions, redundant therapies, side effects, etc.
9. Compliance updates and consultations
10. Staff Training
11. Exceptional customer service.
Toll Free: 888-919-7411 Phone: 305-919-7399 Fax: 305-919-7424
HOURS
Monday- Thursday 8:30 AM - 6:30 PM
Friday 8:30 AM - 6:00 PM
Saturday 11:00 AM - 4:00 PM
PharmCo currently services: Miami-Dade, Broward, Palm Beach, Martin, and St. Lucie Counties.
Progressive Care Reports Full Year 2021 Financial Results Highlighted by $38.9 Million in RevenueGLOBENEWSWIRE – 11:16 AM ET 03/29/2022 |
Progressive Care’s PharmcoRx Gains Status as Approved COVID-19 Test Vendor in the U.S. for Travel to Beijing Winter Olympic Games in ChinaGLOBENEWSWIRE – 7:00 AM ET 02/02/2022
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |